Cevimeline

Research use only, not for human use.

A potent M1-selective muscarinic agonist.

A potent M1-selective muscarinic agonist; decreases the K+-evoked [3H]ACh release from hippocampal synaptosomes and increases the K+-evoked [3H]DA release from striatal synaptosomes; attenuates cognitive dysfunctions in AF64A-treated rats with low toxicity.Other Indication Approved

In digested parotid cells, Cevimeline (0.1-100 μM) increases the intracellular Ca2+ concentration.

Cevimeline (0.008-0.016 mg/kg; intraperitoneal injection; male Wistar rats) treatment shows slowly increasing and lasting salivation, and increased blood flow increment in the parotid gland and pressor response. Cevimeline inhibits angiotensin II-induced water intake and neuronal activity in the subfornical organ at 0.016 mg/kg. Animal Model:Male Wistar rats (8-week-old) injected with angiotensin-II Dosage:0.008 mg/kg, 0.016 mg/kg Administration:Intraperitoneal injectionResult:Showed slowly increasing and lasting salivation, and increased blood flow increment in the parotid gland and pressor response.

AF-102B | FKS-508

GPCR/G Protein

mAChR

mAChR

Other Indications

Other Disease

107233-08-9

199.3131

C10H17NOS

>98% (HPLC)

10 mM in DMSO

C[C@H]1O[C@]2(CS1)CN3CCC2CC3

Spiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane], 2'-methyl-, (2'R,3R)-rel-

(-20℃)

With Ice Pack

≥ 2 years